Previous studies report that serum IGFBP‐2 concentrations are elevated in a stage‐dependent manner in patients with numerous malignancies, including colorectal 9, prostate 10, ovarian 11, and lung 12 cancers, and might be prognostic, while serum IGFBP‐3 is implicated as prognostic in patients with metastatic colorectal cancer undergoing chemotherapy 13. This evidence concerns the gene IGFBP2 and cancer.